|
|
Article: "Big Pharma' Turns To Biologics For Growth To 2010: Financial And Strategic Segmentation Of The 'Big Pharma' Sector By Drug Technology" by Datamonitor.
- Article from:
- M2 Presswire
- Article date:
- June 5, 2006
CopyrightCOPYRIGHT 2006 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-5 June 2006-MindBranch: "Big Pharma' Turns To Biologics For Growth To 2010: Financial And Strategic Segmentation Of The 'Big Pharma' Sector By Drug Technology" by Datamonitor(C)1994-2006 M2 COMMUNICATIONS LTD
RDATE:02062006
'Big Pharma' (non-biotech companies with annual revenues >$10bn) has historically focused on small molecules. However, this is set to change, with around 60% of revenue growth forecast to come from biologic products (therapeutic proteins and monoclonal antibodies): by 2010, annual sales of biologics will have increased by $26bn, compared to a $13bn increase for small molecules.
Scope Global sales forecasts for ...